Acute Febrile Illness
15
3
3
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
13%
2 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
Causes and Outcomes of Febrile Illness in Health Facilities in Rural South and Southeast Asia
AI-Guided Proteomic Biomarker Panel for Differentiating Bacterial and Viral Infections in Acute Febrile Illness
Transcriptomic Responses for the Identification of Pathogens
Clinical Study of Transcriptome-based Diagnostic Biomarker for Acute Febrile Illness
Advancing Access to Diagnostic Innovation Essential for UHC and AMR Prevention
Diagnostic Accuracy of the DPP II Assay
Comparison of Rates of Antimicrobial Use in Febrile Patients With or Without the Use of C-reactive Protein Blood Test
The Etiology of Acute Febrile Illness Requiring Hospitalization
Improving Nighttime Access to Care and Treatment (Part 2)
Cluster Randomised Trial of Malaria RDTs Used by CHWs in Afghanistan
Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal
Acute Undifferentiated Fever in Ethiopia
Evaluation of the DPP II Assay in Laos
Electronic Algorithms Based on Host Biomarkers to Manage Febrile Children